| # | Drug | Count |
|---|---|---|
| 0 | IPILIMUMAB | 284 |
| 1 | NIVOLUMAB | 273 |
| 2 | CARBOPLATIN | 67 |
| 3 | INFLIXIMAB | 47 |
| 4 | METHYLPREDNISOLONE | 43 |
| 5 | PANTOPRAZOLE | 37 |
| 6 | PREDNISOLONE | 36 |
| 7 | PREDNISOLONE ORAL | 36 |
| 8 | PREDNISOLONE ORAL SOLUTION | 36 |
| 9 | PEMETREXED DISODIUM | 34 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | IPILIMUMAB | 284 | 0.0065 |
| 1 | COUMARIN | 1 | 0.0061 |
| 2 | DOXERCALCIFEROL | 1 | 0.0060 |
| 3 | TALIMOGENE LAHERPAREPVEC | 7 | 0.0044 |
| 4 | TRASTUZUMAB-DKST | 1 | 0.0036 |
| 5 | COBIMETINIB | 14 | 0.0032 |
| 6 | NIVOLUMAB | 273 | 0.0028 |
| 7 | BARIUM SULFATE | 1 | 0.0023 |
| 8 | NIVOLUMAB AND RELATLIMAB-RMBW | 1 | 0.0019 |
| 9 | ALLOPURINOL SODIUM | 1 | 0.0018 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | CTLA-4-directed Blocking Antibody [EPC] | 290 | 0.0060 |
| 1 | Programmed Death Receptor-1 Blocking Antibody [EPC] | 463 | 0.0047 |
| 2 | Lymphocyte Activation Gene-3 Blocker [EPC] | 1 | 0.0019 |
| 3 | Macrolide Antibacterial [EPC] | 1 | 0.0010 |
| 4 | Programmed Death Ligand-1 Blocker [EPC] | 16 | 0.0007 |
| 5 | Chemokine Receptor Type 4 Interaction [EPC] | 1 | 0.0007 |
| 6 | Non-Standardized Fungal Allergenic Extract [EPC] | 1 | 0.0005 |
| 7 | Lipid-based Polyene Antifungal [EPC] | 4 | 0.0003 |
| 8 | CD19-directed Chimeric Antigen Receptor [EPC] | 3 | 0.0003 |
| 9 | Phenothiazine [EPC] | 8 | 0.0003 |